FDG PET/CT Findings of Thymic Carcinoid and Bronchial Carcinoid in a Patient With Multiple Neuroendocrine Neoplasia Type1

Abe, Takashi; Sato, Motohiro; Okumura, Toshiyuki; Shioyama, Yasukazu; Kiyoshima, Moriyuki; Asato, Yuji; Saito, Hitoaki; Iijima, Tatsuo; Amemiya, Ryuta; Nagai, Hideo

doi:10.1097/rlu.0b013e318187efef

Cited by 12 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apart from postoperative changes no other abnormality was noted at the primary site (c). A diagnosis of distant recurrence was made and confirmed on CT-guided biopsy usually not 18F-FDG avid, thymic carcinoids are usually 18F-FDG avid (30) (Fig. 11).…”

Section: Thymic Carcinoidmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of thymic tumors with 18F-FDG PET-CT: A pictorial review

et al. 2013

View full text Add to dashboard Cite

Thymic tumors represent a broad spectrum of neoplastic disorders and pose considerable diagnostic difficulties. A non-invasive imaging study to determine the nature of thymic lesions can have significant impact on management of such tumors. 18F-flurorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) has shown promising results in characterization of thymic tumors. The objective of this article is to provide an illustrative tutorial highlighting the clinical utility of 18F-FDG PET-CT imaging in patients with thymic tumors. We have pictorially depicted the 18F-FDG PET-CT salient imaging characteristics of various thymic tumors, both epithelial and non-epithelial. Also discussed is the dynamic physiology of thymus gland which is to be kept in mind when evaluating thymic pathology on 18F-FDG PET-CT, as it can lead to interpretative pitfalls.

show abstract

Section: Thymic Carcinoidmentioning

confidence: 99%

“…The mass showed areas of necrosis (arrows) and 18F-FDG uptake in non-necrotic parts (SUVmax 2.3). In the given clinical scenario diagnosis of thymic carcinoid was made on 18F-FDG PET-CT and confirmed on biopsy usually not 18F-FDG avid, thymic carcinoids are usually 18F-FDG avid (30) (Fig. 11).…”

Section: Thymic Carcinoidmentioning

confidence: 99%

Evaluation of thymic tumors with 18F-FDG PET-CT: A pictorial review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Abe and coworkers presented a case of simultaneous occurrence of thymic and bronchial carcinoid of a MEN1 patient. In this patient, 18F-FDG PET/CT visualized the thymic carcinoid, but did not detect the bronchial carcinoid (Abe et al 2008).…”

Section: Bronchial and Thymic Carcinoidmentioning

confidence: 57%

The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies

Manoharan¹,

Albers²,

Bartsch³

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prospective randomized data are lacking, but current clinical expert guidelines recommend annual screening examinations, including laboratory assessments and various imaging modalities (e.g. CT, MRI, scintigraphy and EUS) for patients with multiple endocrine neoplasia type 1 (MEN1). Routine screening is proposed to detect and localize neuroendocrine manifestations as early as possible. The goal is timely intervention to improve quality of life and to increase life expectancy by preventing the development of life-threatening hormonal syndromes and/or metastatic disease. In recent years, some studies compared different and new imaging methods regarding their sensitivity and utility in MEN1 patients. This present article reviews the proposed diagnostic tools for MEN1 screening as well as potential future perspectives.

show abstract

“…Conventional somatostatin receptor scintigraphy has a lower sensitivity (around 75%) to detect thymic NET (Gibril, et al 2003). Imaging by 18 F-fluorodeoxyglucose (FDG) PET/CT may be useful to detect locally invasive lesions and distant metastases (Abe, et al 2008; Recuero Diaz, et al 2013). CT-guided needle biopsy of thymic NET or bronchoscopic biopsy of bronchial NET, followed by pathological examination of the specimens, help confirm diagnosis after clinical evaluation and radiological workup.…”

Section: Bronchial and Thymic Neuroendocrine Tumors In Men1mentioning

confidence: 99%

Endocrine neoplasms in familial syndromes of hyperparathyroidism

Li¹,

Simonds²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Familial syndromes of hyperparathyroidism, including multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), and the hyperparathyroidism-jaw tumor (HPT-JT), comprise 2 to 5% of primary hyperparathyroidism cases. Familial syndromes of hyperparathyroidism are also associated with a range of endocrine and non-endocrine tumors, including potential malignancies. Complications of the associated neoplasms are the major causes of morbidities and mortalities in these familial syndromes, e.g., parathyroid carcinoma in HPT-JT syndrome, thymic, bronchial and enteropancreatic neuroendocrine tumors in MEN1, and medullary thyroid cancer and pheochromocytoma in MEN2A. Because of the different underlying mechanisms of neoplasia, these familial tumors may have different characteristics compared to their sporadic counterparts. Large-scale clinical trials are frequently lacking due to the rarity of these diseases. With technological advances and the development of new medications, the natural history, diagnosis and management of these syndromes are also evolving. In this article, we summarize the recent knowledge on endocrine neoplasms in three familial hyperparathyroidism syndromes, with an emphasis on disease characteristics, molecular pathogenesis, recent developments in biochemical and radiological evaluation, and expert opinions on surgical and medical therapies. Because these familial hyperparathyroidism syndromes are associated with a wide variety of tumors in different organs, this review is focused on those endocrine neoplasms with malignant potential.

show abstract

FDG PET/CT Findings of Thymic Carcinoid and Bronchial Carcinoid in a Patient With Multiple Neuroendocrine Neoplasia Type1

Cited by 12 publications

References 11 publications

Evaluation of thymic tumors with 18F-FDG PET-CT: A pictorial review

Evaluation of thymic tumors with 18F-FDG PET-CT: A pictorial review

The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies

Endocrine neoplasms in familial syndromes of hyperparathyroidism

Contact Info

Product

Resources

About